Fractyl Health (GUTS) Gross Profit (2023 - 2024)
Fractyl Health (GUTS) reported Gross Profit of $3000.0 for Q4 2024, down 40.0% year-on-year from $5000.0 in Q1 2024, and down 57.14% quarter-over-quarter from $7000.0 in Q3 2024.
Fractyl Health (GUTS) has 2 years of Gross Profit data on file, last reported at $3000.0 in Q4 2024.
- For the quarter ending Q4 2024, Gross Profit fell 40.0% year-over-year to $3000.0; the trailing twelve-month figure through Dec 2024 stood at $43000.0 (changed 0.0% YoY), and the FY2024 full-year result was $43000.0, changed 0.0% from the prior year.
- Gross Profit for Q4 2024 stood at $3000.0, down from $7000.0 in the prior quarter.
- Across five years, Gross Profit topped out at $25000.0 in Q2 2023 and bottomed at $2000.0 in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Dec 31, 2023 | 5,000.00 |
| Dec 31, 2023 | 5,000.00 |
| Sep 30, 2023 | 11,000.00 |
| Sep 30, 2023 | 11,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Mar 31, 2023 | 2,000.00 |